0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Food and Drug Administration |

New Treament for Eczema

Bernard A. Schwetz, DVM, PhD
JAMA. 2001;285(6):724. doi:10.1001/jama.285.6.724.
Text Size: A A A
Published online

Extract

The FDA has approved tacrolimus ointment (Protopic; Fujisawa Healthcare, Deerfield, Ill) for short-term and intermittent long-term therapy for patients with moderate to severe atopic dermatitis in whom the use of coventional therapies is inadvisable or not adequately effective.The indication is for 0.03% and 0.1% tacrolimus for adults and 0.03% for children 2 to 15 years.

The FDA approval was based on results of three randomized, vehicle-controlled, 12-week studies and two 1-year studies with patients with moderate to severe eczema who were not refractory to other treatment. One of the 12-week studies included 351 patients 2-15 years of age, and the other two included a total of 632 patients aged 15-79 years. At baseline, 58% of the patients had severe disease; the mean body surface area affected was 46%. More than 80% of patients had eczema affecting the face and/or neck region.

Topics

eczema

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();